Labrys is preparing to evaluate the antibody’s efficacy in patients with chronic migraine in phase II studies. The company will continue to confirm the molecule’s safety and determine the dose to be tested in phase III trials. Phase II studies are being developed and are soon to be initiated, said Dr. Bigal.
The development of Amgen’s antibody also is ongoing. “The AMG 334 profile supports progression into phase II,” said Dr. Xu.
—Erik Greb
Senior Associate Editor